Share
Other content recommended for you
- International experience of paying for expensive medicines
- A sixth of hospitals in England have expanded private patient options this year, the BMJ finds
- Should NHS patients be allowed to contribute extra money to their care?
- Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer
- Targeted treatments in colorectal cancer: state of the art and future perspectives
- Patients in England are given green light to buy drugs privately alongside NHS care
- Will the fudge on equity sustain the NHS into the next millennium?
- A Postmarketing Surveillance Study on Erbitux (Cetuximab) in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-Containing Treatment
- Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial
- Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer